Yu Nishioka

495 total citations
8 papers, 383 citations indexed

About

Yu Nishioka is a scholar working on Molecular Biology, Genetics and Neurology. According to data from OpenAlex, Yu Nishioka has authored 8 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 1 paper in Genetics and 1 paper in Neurology. Recurrent topics in Yu Nishioka's work include Genomics and Chromatin Dynamics (4 papers), RNA Research and Splicing (3 papers) and Nuclear Structure and Function (3 papers). Yu Nishioka is often cited by papers focused on Genomics and Chromatin Dynamics (4 papers), RNA Research and Splicing (3 papers) and Nuclear Structure and Function (3 papers). Yu Nishioka collaborates with scholars based in Japan and United States. Yu Nishioka's co-authors include Nariaki Matsuura∥, Miki Hieda, Yuhki Yokoyama, Ayaka Matsumoto, Masahiko Tsujimoto, Katsuhide Yoshidome, Hiroshi Kimurâ, Shuji Matsuura, Masaki Mori and Hirofumi Yamamoto and has published in prestigious journals such as Blood, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Yu Nishioka

8 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Nishioka Japan 6 323 72 52 48 23 8 383
Guillaume Davidson France 9 217 0.7× 47 0.7× 65 1.3× 91 1.9× 48 2.1× 16 297
Ineke Kuper Netherlands 5 289 0.9× 53 0.7× 52 1.0× 82 1.7× 20 0.9× 5 342
Tianmu Wen United States 8 166 0.5× 91 1.3× 26 0.5× 54 1.1× 27 1.2× 13 260
Lorena A. Puto United States 6 246 0.8× 40 0.6× 59 1.1× 87 1.8× 43 1.9× 6 320
Xuezhu Rong China 11 249 0.8× 107 1.5× 84 1.6× 64 1.3× 18 0.8× 21 328
Takao Morinaga Japan 9 151 0.5× 62 0.9× 29 0.6× 70 1.5× 17 0.7× 23 229
Sofia M.E. Weiler Germany 8 178 0.6× 113 1.6× 48 0.9× 52 1.1× 40 1.7× 11 263
Philip Bland United Kingdom 6 112 0.3× 55 0.8× 41 0.8× 34 0.7× 16 0.7× 8 210
Tiago Gomes Spain 6 268 0.8× 43 0.6× 41 0.8× 52 1.1× 22 1.0× 8 327
Aaron R. Tipton United States 10 286 0.9× 179 2.5× 25 0.5× 63 1.3× 35 1.5× 18 344

Countries citing papers authored by Yu Nishioka

Since Specialization
Citations

This map shows the geographic impact of Yu Nishioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Nishioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Nishioka more than expected).

Fields of papers citing papers by Yu Nishioka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Nishioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Nishioka. The network helps show where Yu Nishioka may publish in the future.

Co-authorship network of co-authors of Yu Nishioka

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Nishioka. A scholar is included among the top collaborators of Yu Nishioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Nishioka. Yu Nishioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Hatakeyama, Mariko, Hiroshi Ohmoto, Kyoko Miyamoto, et al.. (2024). Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers. Blood. 144(Supplement 1). 1850–1850. 1 indexed citations
2.
Endo, Hiroko, et al.. (2024). Abstract 5714: Synergistic effect of the CDC7 inhibitor, monzosertib (AS-0141) with current therapies in AML models. Cancer Research. 84(6_Supplement). 5714–5714. 1 indexed citations
3.
Nishioka, Yu, et al.. (2016). SUN1 splice variants, SUN1_888, SUN1_785, and predominant SUN1_916, variably function in directional cell migration. Nucleus. 7(6). 572–584. 38 indexed citations
4.
Matsumoto, Ayaka, Miki Hieda, Yuhki Yokoyama, et al.. (2015). Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin‐2 in breast cancer. Cancer Medicine. 4(10). 1547–1557. 111 indexed citations
5.
Hieda, Miki, Yu Nishioka, Ayaka Matsumoto, et al.. (2015). SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3. Experimental Cell Research. 334(1). 90–99. 35 indexed citations
6.
Yokoyama, Yuhki, Ayaka Matsumoto, Miki Hieda, et al.. (2014). Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Research. 16(3). R66–R66. 69 indexed citations
7.
Yokoyama, Yuhki, Miki Hieda, Yu Nishioka, et al.. (2013). Cancer‐associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Science. 104(7). 889–895. 108 indexed citations
8.
Tanaka, Hisae, Yu Nishioka, Yuhki Yokoyama, et al.. (2012). Nuclear envelope-localized EGF family protein amphiregulin activates breast cancer cell migration in an EGF-like domain independent manner. Biochemical and Biophysical Research Communications. 420(4). 721–726. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026